In line with this notion, RNA sequencing analysis of Brca2 mutant cancers that were either sensitive or resistant to PARP inhibition did not provide evidence that EMI1 loss is involved in PARP inhibitor resistance (Supplementary Fig. 7D). The gene discussed is FBXO5; the disease is cancer.